CSL Biotherapies, a subsidiary of CSL Ltd., has been awarded a contract by the U.S. Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services for the U.S. stockpile. The contract has a maximum potential value of $1.5 billion if all options are exercised under the contract.   CSL Biotherapies may manufacture and store bulk antigen for influenza strains with pandemic potential, as well as develop working virus ‘seeds’ for other ma...